jenburkt pharmaceuticals has closed its trading window for all designated persons, insiders, and connected persons, including their relatives, effective July 1, 2026. This measure is in accordance with the company’s Code on Prohibition of Insider Trading and the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The restriction is implemented to prevent potential insider trading ahead of the release of price-sensitive information.

The trading window will remain closed until 48 hours after the company disseminates the standalone unaudited financial results for the quarter ending June 30, 2026. This closure ensures that no insider trades occur while the market is unaware of the quarterly performance data. The company stated that the specific schedule for the board meeting, which will consider these unaudited financial results, will be communicated to the exchange separately at a later date.

The closure applies to all trades in the equity shares of Jenburkt Pharmaceuticals Limited by the specified individuals. The notification was signed by Ashish Rasiklal Shah, Senior Vice President, Company Secretary, and Compliance Officer. The company has requested the stock exchange to take the closure of the trading window on record.

Jenburkt Pharmaceuticals Limited has formally published its standalone audited financial results for the quarter and financial year ended on March 31, 2026. The announcement was made in compliance with Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was communicated to BSE Ltd. on May 6, 2026.

Board Approval and Regulatory Compliance

The Board of Directors of Jenburkt Pharmaceuticals convened on Tuesday, May 5, 2026, and approved the standalone audited financial results for the quarter and financial year ended on March 31, 2026. The filing was submitted to BSE Ltd. under Script Code 524731, with the formal intimation letter bearing reference number JPL/CS/2308/2025, signed by Ashish R. Shah, Sr. Vice President, Company Secretary, and Compliance Officer.

Newspaper Publications

In accordance with regulatory requirements, the standalone audited financial results were published in the following newspapers on May 6, 2026:

• The Free Press Journal, Mumbai (English)
• Navshakti, Mumbai (Marathi)

These publications serve as the official public disclosure of the company's audited financial results for the relevant period.

Availability of Financial Results

The complete financial results of Jenburkt Pharmaceuticals are available for public access through the following channels:

• BSE India website: www.bseindia.com
• Company website: https://jenburkt.com/investors/financial-results

Stakeholders and investors may access the full format of the financial results through either of these platforms. The company has also made the results accessible via a Quick Response (QR) code published alongside the official announcement.

Company Overview

Jenburkt Pharmaceuticals Limited is registered under CIN: L24230MH1985PLC036541, with its registered office at Nirmala Apartments, 93, J. P. Road, Andheri (West), Mumbai – 400 058. The company, which marks 40 years of excellence in healthcare, operates under the tagline "Delivering Excellence in Life Sciences." The filing underscores the company's continued adherence to SEBI's listing and disclosure obligations.